Are Wall Street Analysts Predicting Henry Schein Stock Will Climb or Sink?
/Henry%20Schein%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shuttestock.jpg)
Henry Schein, Inc. (HSIC), based in Melville, New York, is a leading global distributor of healthcare products and services, catering mainly to dental and medical professionals. With a market capitalization of $8.8 billion, the company delivers a wide range of offerings, from consumables and pharmaceuticals to equipment and technology solutions.
HSIC shares have lagged the broader market over the past year, declining 3.7% compared to the S&P 500 Index ($SPX) 12.5% surge. However, in 2025, the stock has gained momentum, climbing 3.8%, outpacing the SPX’s 1.4% advance.
Focussing on its industry benchmark, SPDR S&P Health Care Services ETF (XHS) has risen 9.5% over the past year and 11.2% in 2025, surpassing the stock.
On May 5, Henry Schein reported Q1 results, and its shares rose 2%. It posted adjusted earnings of $1.15 per share, surpassing Wall Street expectations of $1.11. However, revenue came in at $3.17 billion, a 1.4% year-over-year increase in constant currency terms, but slightly below the anticipated $3.24 billion.
Henry Schein reaffirmed its full-year 2025 guidance, projecting adjusted EPS between $4.80 and $4.94, and anticipates stronger performance in the second half of the year.
For the current year ending in December, analysts expect HSIC’s EPS to grow 2.3% to $4.85 on a diluted basis. The company’s earnings surprise history is solid. It met or surpassed the consensus estimate in each of the last four quarters.
Among the 14 analysts covering HSIC stock, the consensus is a “Moderate Buy.” That’s based on six “Strong Buy” ratings, seven “Holds,” and one “Strong Sell.”
On May 6, Barrington Research lowered its price target for Henry Schein from $90 to $86, which is also the Street-high price target, and maintained its 'Outperform' rating. The revised target reflects an updated analysis, but the continued positive rating signals the firm's confidence in Henry Schein’s potential to outperform the broader market.
HSIC’s mean price target of $76.54 represents a premium of 6.5% from the current market prices.
On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.